ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries
Open Access
- 10 March 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 363
Abstract
The biopharmaceutical classification system (BCS) is a very important tool to replace the traditional in vivo bioequivalence studies with in vitro dissolution assays during multisource product development. This paper compares the most recent harmonized guideline for biowaivers based on the biopharmaceutics classification system and the BCS regulatory guidelines in Latin America and analyzes the current BCS regulatory requirements and the perspective of the harmonization in the region to develop safe and effective multisource products. Differences and similarities between the official and publicly available BCS guidelines of several Latin American regulatory authorities and the new ICH harmonization guideline were identified and compared. Only Chile, Brazil, Colombia, and Argentina have a more comprehensive BCS guideline, which includes solubility, permeability, and dissolution requirements. Although their regulatory documents have many similarities with the ICH guidelines, there are still major differences in their interpretation and application. This situation is an obstacle to the successful development of safe and effective multisource products in the Latin American region, not only to improve their access to patients at a reasonable cost, but also to develop BCS biowaiver studies that fulfill the quality standards of regulators in developed and emerging markets.Keywords
This publication has 14 references indexed in Scilit:
- Policy of Multisource Drug Products in Latin America: Opportunities and Challenges on the Application of Bioequivalence In Vitro AssaysTherapeutic Innovation & Regulatory Science, 2020
- ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ ConsortiumMolecular Pharmaceutics, 2019
- The Discriminatory Power of the BCS-Based Biowaiver: A Retrospective With Focus on Essential MedicinesJournal of Pharmaceutical Sciences, 2019
- Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicinesBiopharmaceutics & Drug Disposition, 2018
- A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators ProgrammeJournal of Pharmacy & Pharmaceutical Sciences, 2018
- BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO RequirementsThe AAPS Journal, 2016
- Generic and similar products in Latin American countries: Current aspects and perspectives on bioequivalence and biowaiversPharmaceuticals Policy and Law, 2014
- The BCS, BDDCS, and Regulatory GuidancesPharmaceutical Research, 2011
- Impact of Biopharmaceutics Classification System-Based BiowaiversMolecular Pharmaceutics, 2010
- A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo BioavailabilityPharmaceutical Research, 1995